Author:
Doppenberg Deesje,van Veldhuisen E.,Busch O. R.,van Tienhoven G.,Wilmink J. W.,Besselink Marc. G.
Publisher
Springer International Publishing
Reference52 articles.
1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20.
2. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2012;10(6):703–13.
3. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–9.
4. Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014;20(31):10740–51.
5. The Royal College of Pathologists. Dataset for the histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma; 2017. https://www.rcpath.org/resourceLibrary/g091-pancreasdataset-mar17.html.